EUVIMEDEUVIMED entdecken
Crossref

Unveiling Remyelinating Properties of Roflumilast in CPZ‐Induced Neuronal Demyelination in Mice

Ahmed S Kamel, Israa Sameh, Mohamed A Khattab, Ayman E El-Sahar iD, Hala F Zaki, Osama A Badary, Sama M Farrag

Drug Development Research · 2026-06 · 87 (4)

DOI: 10.1002/ddr.70329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 28.05.2026. Verfasst von Ahmed S Kamel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Giza, Egypt. Hauptthemen laut MEDLINE: Benzamides, Phosphodiesterase 4 Inhibitors, Aminopyridines, Demyelinating Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 88 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a demyelinating disorder characterized by oligodendrocyte apoptosis, microglial activation at demyelination sites, with ROS production. These pathological processes are closely associated with phosphodiesterase‐4 (PDE‐4) activity. Roflumilast (ROFL), a selective PDE‐4 inhibitor, has demonstrated neuroprotective effects in various central nervous system disorders. However, its specific role in MS pathogenesis remains to be fully elucidated. This study aims to investigate the effects of ROFL on oligodendrocyte maturation, microglial polarization and the impact on protein kinase A/cAMP‐response element binding protein pathway. An MS model was induced in mice via dietary administration of cuprizone (CPZ) for 7 days, starting with 0.7% (w/w), followed by 0.2% for 5 weeks. Beginning in week 5, mice received ROFL (5 mg/kg/day, p.o) for 2 weeks. ROFL improved the motor abnormalities in the rotarod and open field tests. Together, ROFL downregulated the PDE4/cAMP‐dependent pathway, exerting anti‐inflammatory effects by suppressing NF‐κB and TNF‐α. Additionally, microglial polarization shifted toward the anti‐inflammatory M2 phenotype, with CD163 increment, in contrast to the pro‐inflammatory M1 marker CD83. Furthermore, ROFL's antioxidant capacity was evidenced by reduced malondialdehyde levels, replenishment of glutathione levels, and reduced phosphorylation of ERK1/2. Oligodendrocyte differentiation and maturation were enhanced, as indicated by elevated levels of proteolipid protein, myelin‐associated glycoprotein, CNPase, and myelin basic protein. Remyelination was confirmed through Luxol fast blue staining, accompanied by reduced apoptotic marker, caspase‐3, in oligodendrocytes. Collectively, these findings suggest that ROFL exerts neuroprotective effects and highlight the therapeutic potential of PDE‐4 inhibition as a strategy for MS treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzamidesPhosphodiesterase 4 InhibitorsAminopyridinesDemyelinating DiseasesMultiple SclerosisNeuroprotective AgentsRemyelinationAnimalsCyclopropanesMiceCuprizoneOligodendrogliaMicrogliaMaleDisease Models, AnimalMice, Inbred C57BLCyclic AMP-Dependent Protein KinasesTumor Necrosis Factor-alpha

Stichwörter der Autor:innen

PDE‐4multiple sclerosisneuroinflammationoligodendrocytes apoptosisremyelinationroflumilast

Substanzen

RoflumilastCyclopropanesBenzamidesPhosphodiesterase 4 InhibitorsCuprizoneAminopyridinesNeuroprotective AgentsCyclic AMP-Dependent Protein KinasesTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Giza, Egypt.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy and Drug Technology, Egyptian Chinese University, Cairo, Egypt.
  • Postgraduate program in Pharmacology and Toxicology department, Faculty of Pharmacy, Cairo University, Giza, Egypt.
  • Department of Cytology and Histology, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.
  • Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
  • Clinical Pharmacy Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology (MUST), 6th of October City, Giza, Egypt.

ORCID-Profile: Ayman E El-Sahar

Zitieren

APA

Kamel, A. S., Sameh, I., Khattab, M. A., El-Sahar, A. E., Zaki, H. F., Badary, O. A., & Farrag, S. M. (2026). Unveiling Remyelinating Properties of Roflumilast in CPZ‐Induced Neuronal Demyelination in Mice. Drug Development Research, 87(4). https://doi.org/10.1002/ddr.70329

Vancouver

Kamel AS, Sameh I, Khattab MA, El-Sahar AE, Zaki HF, Badary OA, et al. Unveiling Remyelinating Properties of Roflumilast in CPZ‐Induced Neuronal Demyelination in Mice. Drug Development Research. 2026;87(4). doi:10.1002/ddr.70329

BibTeX
@article{Kamel2026,
  author = {Kamel, Ahmed S and Sameh, Israa and Khattab, Mohamed A and El-Sahar, Ayman E and Zaki, Hala F and Badary, Osama A and Farrag, Sama M},
  title = {Unveiling Remyelinating Properties of Roflumilast in CPZ‐Induced Neuronal Demyelination in Mice},
  journal = {Drug Development Research},
  year = {2026},
  volume = {87},
  number = {4},
  doi = {10.1002/ddr.70329}
}
Kostenlos starten →